ALI Post Radiation Therapy for Thoracic Cancers
Trial Summary
What is the purpose of this trial?
The goal of this clinical research study is to learn if giving autologous lymphocyte infusions to patients who are receiving chemotherapy and radiation for non-small cell lung cancer or esophageal cancer is safe and effective.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, any systemic therapy (treatment affecting the whole body) aside from standard immunotherapy should not be planned for at least 6 weeks after the autologous lymphocyte infusion.
What data supports the effectiveness of the treatment Autologous lymphocyte infusion (ALI) for thoracic cancers?
Research shows that tumor infiltrating lymphocytes (TIL), which are similar to the cells used in ALI, can recognize and destroy cancer cells in lung cancer. These TILs can be expanded in the lab and have shown potential in treating cancer, suggesting that ALI might be effective for thoracic cancers.12345
Is autologous lymphocyte infusion (ALI) safe for humans?
The safety of treatments combining immunotherapy and thoracic radiation therapy has been studied, showing that patients may experience immune-related side effects. However, specific safety data for autologous lymphocyte infusion (ALI) itself is not directly available from the provided research.678910
How does the ALI Post Radiation Therapy treatment for thoracic cancers differ from other treatments?
This treatment is unique because it uses adoptive immunotherapy, which involves expanding and reinfusing a patient's own tumor-infiltrating lymphocytes (TILs) to target cancer cells. Unlike traditional chemotherapy or radiation, this approach harnesses the body's immune system to specifically attack cancer cells, potentially offering a more targeted and personalized treatment option.13111213
Research Team
Gheath Al-Atrash
Principal Investigator
MD Anderson Cancer Center, Houston, Texas
Eligibility Criteria
This trial is for adults over 18 with non-small cell lung cancer or esophageal cancer at stages II-IVA, where chemoradiation is standard. Participants must not have had prior chest radiotherapy, any systemic therapy other than standard immunotherapy before 6 weeks after ALI, be pregnant, or have a life expectancy under 6 months.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Radiation/Chemoradiation
Participants undergo radiation or chemoradiation therapy as part of their cancer treatment
Autologous Lymphocyte Infusion (ALI)
Participants receive autologous lymphocyte infusions to improve lymphocyte counts after radiation/chemoradiation
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Autologous lymphocyte infusion (ALI)
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor